YARW — Yarrow Bioscience, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1566044 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2020 3,269,000 2,898,000 23,491,000 24,714,000 93,742,000 57,563,000 56,249,000
Dec 2019 0 0 23,199,000 23,161,000 81,159,000 43,759,000 63,584,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-73,503,000
Investing CF
Financing CF
$99,854,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-08-02

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 501,000 -43,637,000 -39,834,000 66,905,000 14,819,000
Dec 2019 15,884,000 0 81,159,000 63,584,000

TTM Snapshot

Revenues TTM
$6,538,000
NetIncome TTM
$95,750,000
OpCashFlow TTM
$0
Assets (Latest)
$93,742,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.02T $1148.84
JNJ JOHNSON & JOHNSON $617.78B $256.35
ABBV AbbVie Inc. $443.36B $250.94
MRK Merck & Co., Inc. $321.57B $130.20
NVSEF NOVARTIS AG $301.30B $158.52

News headlines (Yahoo Finance, 1h cache)

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye D
2026-07-27 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.